Connect with us
Eli Lilly has partnered with Dresden-based Seamless Therapeutics to develop a recombinase-based gene therapy for genetically caused hearing loss. Seamless will engineer precise recombinases, while Lilly...
In 2025, medical research accelerated toward precision and personalized care. Gene editing and gene therapies matured into real treatments, AI transformed diagnosis and drug discovery, and...
A Carlos III Health Institute team showed CRISPR-based gene therapy effectively targets Ewing sarcoma in preclinical models. Using a tumor-specific promoter, the treatment avoids harming healthy...